Skip to main content
SP5007,796.70+0.62%DOW53,763.95-0.01%NASDAQ26,802.38+0.80%BTC$63,112.00-0.57%ETH$1,875.52-0.65%GOLD$4,429.80-0.84%OIL$82.00-1.53%
Smart Investors Daily
Sign InSign Up Free
LN

NASDAQ · LNSR

LENSAR, Inc.

Healthcare · Medical - Devices

$6.29

Up+$1.51 (+24.01%)

Updated Aug 13, 2026, 5:18 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
137.6M
P/E ratio
-2.79
Dividend yield
0.00%
52-week range
$4.95 – $11.99
Volume
59.25K
Avg. volume
56.53K

Price performance

LNSR price history

1M range · 21 trading sessions · Daily adjusted prices

LNSR closed at $6.29 after 21 trading sessions, up 10.93% for the selected period.

Last close
$6.29
Period change
+10.93%
Period low
$5.01
Period high
$6.29
Daily close
View OHLC price history
LNSR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 12, 2026$6.09$6.45$6.05$6.2959.25K
Aug 11, 2026$5.95$6.11$5.90$6.0344.97K
Aug 10, 2026$5.96$6.18$5.88$6.0277.7K
Aug 7, 2026$5.79$6.08$5.635$6.0445.97K
Aug 6, 2026$5.78$5.8299$5.5204$5.73521.71K
Aug 5, 2026$5.55$5.83$5.55$5.8314.88K
Aug 4, 2026$5.38$5.66$5.38$5.5847.56K
Aug 3, 2026$5.08$5.48$5.08$5.3846.84K
Jul 31, 2026$5.19$5.22$4.95$5.01111.06K
Jul 30, 2026$5.20$5.29$5.15$5.1728.64K
Jul 29, 2026$5.29$5.35$5.20$5.2543.56K
Jul 28, 2026$5.31$5.42$5.31$5.3528.48K
Jul 27, 2026$5.57$5.57$5.37$5.3749.28K
Jul 24, 2026$5.70$5.90$5.5407$5.6074.41K
Jul 23, 2026$5.69$5.83$5.45$5.7645.49K
Jul 22, 2026$5.78$5.80$5.72$5.7517.92K
Jul 21, 2026$5.74$5.78$5.7301$5.763.61K
Jul 20, 2026$5.74$5.82$5.71$5.7512.48K
Jul 17, 2026$5.64$5.82$5.64$5.8018.52K
Jul 16, 2026$5.69$5.74$5.67$5.6718.77K
Jul 15, 2026$5.77$5.8055$5.6501$5.6713.77K

Latest LNSR news

The latest Smart Investors Daily articles mentioning LNSR.

Stock researchCompany · Overview

LNSR research

Overview

Company profile and research snapshot.

Company profile

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
LNSR recent ratings
DateFirmRatingTarget
Mar 18, 2026BTIGBuy—
Mar 24, 2025Lake StreetHold—
Feb 28, 2025Lake StreetBuy—
Mar 19, 2024Lake StreetBuy—
Nov 22, 2021BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Feb 25, 2026

LENSAR Provides An Update On The Status Of Its Pending Acquisition By Alcon Research; Says The Co. And Alcon Continue To Cooperate With The FTC Staff In Connection With Its Request For Additional Information And Documentary Material; Expects To Close The Transaction In The First Half Of 2026

LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the status of its

defenseworld.net · Dec 4, 2025

LENSAR, Inc. $LNSR Position Increased by Groupe la Francaise

Groupe la Francaise raised its stake in LENSAR, Inc. (NASDAQ: LNSR) by 99.5% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 251,400 shares of the company's stock after buying an additional 125,400 shares during the period. Groupe la Francaise owned approximately 2.11%

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By